timothy sykes logo
BIAF Stock Pops As CyPath Lung Scores Big VA Deal Thumbnail
G Google News

BIAF Stock Pops As CyPath Lung Scores Big VA Deal

JACK KELLOGG•UPDATED SEP. 3, 2026, 7:47 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

BioAffinity Technologies Inc. soared as promising cancer diagnostics news fueled bullish sentiment, and stocks have been trading up by 30.47 percent.

Key Takeaways

  • Nationwide AvMEDICAL deal opens CyPath Lung access to VA and other federal healthcare systems, giving BIAF a powerful government-focused sales channel.
  • Q2 2026 showed CyPath Lung test volume up 216% year over year, with 122% growth in physician accounts and 71% higher orders from existing customers.
  • Despite momentum, BIAF remains deeply loss-making with only about $2.4M in cash at 2026/06/30, recent equity dilution, and ongoing Nasdaq delisting risk.
  • Management is pushing CyPath Lung into post-treatment surveillance for lung cancer survivors, broadening its role beyond early detection.
  • Q2 EPS improved sharply to -$0.64 from -$5.07, while BIAF continues to build a broader pipeline in asthma/COPD diagnostics and siRNA-based skin cancer therapeutics.

Candlestick Chart

Live Update At 07:47:27 EDT: On Thursday, September 03, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 30.47%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has turned into a volatility magnet. The daily chart shows bioAffinity Technologies ripping from sub-$1 levels in mid‑August to a recent close of $9.75 on 2026/09/02 after hitting an intraday high near $11.75. That kind of multi‑bagger move in a couple of weeks is exactly what momentum traders stalk.

Under the hood, BIAF is still early-stage and unprofitable. The company delivered Q2 2026 revenue of $1.5M, up from $1.27M a year earlier, driven mainly by its CyPath Lung diagnostic. Gross margin sits at roughly 52.6%, which is solid for a small-cap diagnostics name, but the problem is scale. Operating expenses of about $4.8M in the quarter left BIAF with a net loss of roughly $3.4M and EBITDA around -$3.3M.

More Breaking News

Cash is tight. At 2026/06/30, BIAF reported roughly $2.4M in cash and equivalents, even after raising about $3.2M via equity in June. That explains the Nasdaq delisting risk hanging over the ticker and the likelihood of more raises if operations do not ramp quickly. For traders, BIAF is a classic high‑reward, high‑risk setup: strong growth metrics, but a fragile balance sheet and heavy dilution overhang.

Why Traders Are Watching BIAF Right Now

This latest run in BIAF is not a random meme spike. It is tied to real news flow and real traction around CyPath Lung, and traders are reacting to that narrative.

First, the AvMEDICAL distribution deal is a big tell. BIAF now has a nationwide federal healthcare distribution agreement for CyPath Lung, plugging directly into the Department of Veterans Affairs and other federal systems through an established government-focused sales force and IDIQ contracting channels. For a micro-cap like bioAffinity Technologies, you rarely get a cleaner commercial validation signal. It does not guarantee volume overnight, but it opens the door to large veteran and military patient pools that were much harder to reach before.

Second, the growth numbers around CyPath Lung are the fuel behind BIAF’s chart. In Q2 2026, test volume jumped 216% year over year, physician accounts rose 122%, and existing customers boosted their orders by 71%. First-half CyPath Lung revenue climbed 159% to roughly $0.8M, lifting total Q2 revenue 19% to $1.5M. Traders love that kind of acceleration, even off a small base, because it suggests product-market fit is forming.

Third, BIAF is not just a single-angle story. The company is advancing a VA- and military-backed longitudinal clinical trial, expanding physician education, and pushing CyPath Lung beyond early detection into post-treatment surveillance for lung cancer survivors. That surveillance angle—monitoring recurrence and new primary tumors alongside imaging—effectively grows the lifetime revenue opportunity per patient. Add in early work on asthma/COPD precision diagnostics and topical siRNA-based skin cancer therapeutics, and you get a mini‑platform narrative that can support blue-sky trading when momentum hits.

The catch is execution and time. The market is clearly willing to pay up for the growth storyline, but BIAF has to convert access and trials into durable revenue before the cash clock runs down.

Conclusion

For active traders, BIAF is a textbook battleground between growth and survival risk. On one side, bioAffinity Technologies is posting eye‑catching operating metrics, with Q2 EPS improving to -$0.64 from a brutal -$5.07 a year earlier and CyPath Lung usage ramping hard. On the other side, margins are still deeply negative, cash burned fast, and Nasdaq delisting risk signals that more equity raises—and more dilution—remain on the table.

The price action reflects that tug‑of‑war. BIAF soared from pennies to double digits in a matter of weeks, fueled by the AvMEDICAL federal channel deal, surging test volume, and expanding indications into survivorship care. The intraday tape shows big swings from $10 to above $14 and back, which is exactly the kind of range that rewards disciplined day traders and punishes bag‑holders.

From an educational standpoint, BIAF is a strong case study in how small-cap biotech news translates into price. A real commercial contract plus real usage growth can ignite a violent re‑rating, even when the balance sheet is weak. But the risk does not go away just because the chart goes vertical.

As Tim Sykes likes to hammer home, “Volatile small caps like this are trading vehicles, not marriages—use the volatility, but don’t let it use you.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” For BIAF, that means respecting both sides of the story: the upside in CyPath Lung’s expansion and the very real funding and listing risks that can slam the stock just as fast as it ran. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”